A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
Recruiting · NCT07411755 · Registry updated 2026-05-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 1 | 2026-05-20 | NCT07411755 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangsu Genscend Biopharmaceutical Co., Ltd | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Second Affiliated Hospital of Soochow University | Suzhou | China | 22 |